Surgical Resection of Primary Tumor for Bone Metastatic Breast Cancer Patients at Initial Presentation

被引：0
作者：
Kitsuya, Nayu [1 ,2 ,3 ]
Matsuoka, Masatake [1 ,2 ]
Onodera, Tomohiro [1 ,2 ]
Yokota, Isao [4 ]
Iwasaki, Koji [5 ]
Suzuki, Yuki [1 ,2 ]
Hamasaki, Masanari [1 ,2 ]
Kondo, Eiji [6 ]
Iwasaki, Norimasa [1 ,2 ]
机构：
[1] Hokkaido Univ, Fac Med, Dept Orthopaed Surg, North 15 West 7,Kita Ku, Sapporo, Hokkaido 0608638, Japan
[2] Hokkaido Univ, Grad Sch Med, North 15 West 7,Kita Ku, Sapporo, Hokkaido 0608638, Japan
[3] Hakodate Cent Gen Hosp, Dept Orthopaed Surg, Hakodate, Japan
[4] Hokkaido Univ, Grad Sch Med, Dept Biostat, Sapporo, Japan
[5] Hokkaido Univ, Dept Funct Reconstruct Knee Joint, Sapporo, Japan
[6] Hokkaido Univ Hosp, Ctr Sports Med, Sapporo, Japan
来源：
ANTICANCER RESEARCH | 2024年 / 44卷 / 04期
关键词：
Key Words; Breast cancer; SEER program; neoplasm grading; retrospective study; treatment outcome; INTERNATIONAL EXPERT CONSENSUS; PRIMARY THERAPY; MECHANISMS; GUIDELINE; METASTASECTOMY; HIGHLIGHTS; WOMEN;
D O I：
10.21873/anticanres.16957
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: The purpose of this study was to investigate whether primary tumor resection in patients with bone metastatic breast cancer has an impact on survival using the Surveillance, Epidemiology, and End Results database, considering subtype classification. Patients and Methods: We included all female patients with bone metastatic breast cancer at initial presentation between 2010 and 2016 with known hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) statuses. Cases showing unknown cause of death or unknown HR/HER2 status were excluded. Survival analysis was performed using Cox proportional hazards modeling to calculate hazard ratios (HZR). Results: Of the 13,450 patients included in this study, 2,073 patients were HR+/HER2+, 8,597 patients were HR+/HER2-, 797 patients were HR-/HER2+, and 1,182 patients were HR- /HER2- (triple -negative). Five-year overall survival (OS) rate was 34.5% in HR+/HER2+, 26.0% in HR+/HER2-, 29.2% in HR-/HER2+ and 8.0% in triple -negative. Triple -negative patients showed the worsen OS [HR+/HER2+: HZR=2.1, 95% confidence interval (CI)=1.9-2.3; HR+/HER2-: HZR= 2.4, 95%CI=2.2-2.6; HR-/HER2+: HZR=1.5, 95%CI=1.31.6]. After excluding patients who died within six months, primary tumor resection prolonged survival in each subtype classification except HR-/HER2+. Conclusion: Patients with triple -negative bone metastatic breast cancer showed unfavorable survival. Primary tumor resection prolonged survival in each subtype except for HR-/HER2+.
引用
收藏
页码：1591 / 1601
页数：11
相关论文
共 40 条
  • [1] Guideline Implementation for Breast Healthcare in Low-income and Middle-income Countries Overview of the Breast Health Global Initiative Global Summit 2007
    Anderson, Benjamin O.
    Yip, Cheng-Har
    Smith, Robert A.
    Shyyan, Roman
    Sener, Stephen F.
    Eniu, Alexandru
    Carlson, Robert W.
    Azavedo, Edward
    Harford, Joe
    [J]. CANCER, 2008, 113 (08) : 2221 - 2243
  • [2] Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
    Badwe, Rajendra
    Hawaldar, Rohini
    Nair, Nita
    Kaushik, Rucha
    Parmar, Vani
    Siddique, Shabina
    Budrukkar, Ashwini
    Mittra, Indraneel
    Gupta, Sudeep
    [J]. LANCET ONCOLOGY, 2015, 16 (13) : 1380 - 1388
  • [3] Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
    Burstein, H. J.
    Curigliano, G.
    Thurlimann, B.
    Weber, W. P.
    Poortmans, P.
    Regan, M. M.
    Senn, H. J.
    Winer, E. P.
    Gnant, M.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (10) : 1216 - 1235
  • [4] Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials
    Chen, Chaoyang
    Li, Ruoming
    Yang, Ting
    Ma, Lingyun
    Zhou, Shuang
    Li, Min
    Zhou, Ying
    Cui, Yimin
    [J]. CLINICAL THERAPEUTICS, 2020, 42 (08) : 1494 - +
  • [5] Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
    Coates, A. S.
    Winer, E. P.
    Goldhirsch, A.
    Gelber, R. D.
    Gnant, M.
    Piccart-Gebhart, M.
    Thuerlimann, B.
    Senn, H. -J.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (08) : 1533 - 1546
  • [6] Bisphosphonates in oncology
    Coleman, Robert E.
    McCloskey, Eugene V.
    [J]. BONE, 2011, 49 (01) : 71 - 76
  • [7] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
    Curigliano, G.
    Burstein, H. J.
    Winer, E. P.
    Gnant, M.
    Dubsky, P.
    Loibl, S.
    Colleoni, M.
    Regan, M. M.
    Piccart-Gebhart, M.
    Senn, H. -J.
    Thurlimann, B.
    Andre, F.
    Baselga, J.
    Bergh, J.
    Bonnefoi, H.
    Brucker, S. Y.
    Cardoso, F.
    Carey, L.
    Ciruelos, E.
    Cuzick, J.
    Denkert, C.
    Di Leo, A.
    Ejlertsen, B.
    Francis, P.
    Galimberti, V.
    Garber, J.
    Gulluoglu, B.
    Goodwin, P.
    Harbeck, N.
    Hayes, D. F.
    Huang, C. -S.
    Huober, J.
    Khaled, H.
    Jassem, J.
    Jiang, Z.
    Karlsson, P.
    Morrow, M.
    Orecchia, R.
    Osborne, K. C.
    Pagani, O.
    Partridge, A. H.
    Pritchard, K.
    Ro, J.
    Rutgers, E. J. T.
    Sedlmayer, F.
    Semiglazov, V.
    Shao, Z.
    Smith, I.
    Toi, M.
    Tutt, A.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (08) : 1700 - 1712
  • [8] The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy
    de Gelder, Rianne
    Heijnsdijk, Eveline A. M.
    Fracheboud, Jacques
    Draisma, Gerrit
    de Koning, Harry J.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (01) : 165 - 172
  • [9] Breast Cancer Statistics, 2015: Convergence of Incidence Rates Between Black and White Women
    DeSantis, Carol E.
    Fedewa, Stacey A.
    Sauer, Ann Goding
    Kramer, Joan L.
    Smith, Robert A.
    Jemal, Ahmedin
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (01) : 31 - 42
  • [10] Domchek SM, 2000, CANCER, V89, P363, DOI 10.1002/1097-0142(20000715)89:2<363::AID-CNCR22>3.0.CO
1234